Johnson & Johnson Ebola Vaccine Data Shows Strong Immune Response
14/9 04:41
(RTTNews) - Johnson & Johnson's (JNJ) Ebola vaccine regimen, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo), demonstrated robust and durable immune response in adults and children (ages 1-17). The two-dose vaccine was also found to be safe and well tolerated, the company said citi...